CR7804A - COMBINED THERAPY FOR THE TREATMENT OF ACUTE LEUKEMIA AND MYELODISPLASIC SYNDROME - Google Patents

COMBINED THERAPY FOR THE TREATMENT OF ACUTE LEUKEMIA AND MYELODISPLASIC SYNDROME

Info

Publication number
CR7804A
CR7804A CR7804A CR7804A CR7804A CR 7804 A CR7804 A CR 7804A CR 7804 A CR7804 A CR 7804A CR 7804 A CR7804 A CR 7804A CR 7804 A CR7804 A CR 7804A
Authority
CR
Costa Rica
Prior art keywords
treatment
syndrome
myelodisplasic
acute leukemia
combined therapy
Prior art date
Application number
CR7804A
Other languages
Spanish (es)
Inventor
Jay Marshall Feingold
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR7804A publication Critical patent/CR7804A/en

Links

Classifications

    • E—FIXED CONSTRUCTIONS
    • E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
    • E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
    • E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices
    • E05F3/04—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes
    • E05F3/10—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction
    • E05F3/108—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction with piston rod protruding from the closer housing; Telescoping closers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • E—FIXED CONSTRUCTIONS
    • E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
    • E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
    • E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan metodos de tratamiento y combinaciones farmaceuticas para el tratamiento de la leucemia aguda, tales como leucemia mielogenosa aguda y sindrome displasico. Los metodos de tratamiento y combinaciones farmaceuticas emplean un conjugado citotoixico de anti-CD33 en comnbinacion con la menos un compuesto seleccionado del grupo que consiste de una antraciclina y un analogo del nucleosido de primidina o purina.Treatment methods and pharmaceutical combinations are provided for the treatment of acute leukemia, such as acute myelogenous leukemia and dysplasic syndrome. The treatment methods and pharmaceutical combinations employ an anti-CD33 cytotoxic conjugate in combination with at least one compound selected from the group consisting of an anthracycline and a primidin or purine nucleoside analog.

CR7804A 2002-11-06 2005-04-25 COMBINED THERAPY FOR THE TREATMENT OF ACUTE LEUKEMIA AND MYELODISPLASIC SYNDROME CR7804A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/035532 WO2004043461A1 (en) 2002-11-06 2002-11-06 Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome

Publications (1)

Publication Number Publication Date
CR7804A true CR7804A (en) 2008-10-29

Family

ID=32311637

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7804A CR7804A (en) 2002-11-06 2005-04-25 COMBINED THERAPY FOR THE TREATMENT OF ACUTE LEUKEMIA AND MYELODISPLASIC SYNDROME

Country Status (10)

Country Link
EP (1) EP1575582A4 (en)
JP (1) JP2006508119A (en)
CN (1) CN1720044A (en)
AU (2) AU2002348178A1 (en)
BR (1) BR0215935A (en)
CA (1) CA2504611A1 (en)
CR (1) CR7804A (en)
MX (1) MXPA05004711A (en)
NO (1) NO20052009L (en)
WO (1) WO2004043461A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7977320B2 (en) 2004-10-29 2011-07-12 The Regents Of The University Of California Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents
EP1661584A1 (en) * 2004-11-26 2006-05-31 Heinz Dr. Faulstich Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy
CA2614321A1 (en) * 2005-07-06 2007-01-18 Kanisa Pharmaceuticals, Inc. Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
ATE521366T1 (en) * 2006-05-27 2011-09-15 Faulstich Heinz Dr APPLICATION OF AMATOXIN CONJUGATES AND PHALLOTOXIN CONJUGATES WITH MACROMOLECLES FOR CANCER THERAPY AND THERAPY OF INFLAMMATION
CN1994293A (en) * 2006-08-18 2007-07-11 上海交通大学医学院附属瑞金医院 Application of oridonin in pharmacy
EP2084527A4 (en) * 2006-11-02 2011-07-27 Seattle Genetics Inc Methods of treating neoplastic, autoimmune and inflammatory diseases
HRP20220428T3 (en) * 2007-02-16 2022-05-27 Rotalec Ip Holdings Llc Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
EP2649997B1 (en) * 2007-12-10 2019-01-23 Sunesis Pharmaceuticals, Inc. (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for use in the treatment of myelodyspastic syndrome
WO2010024374A1 (en) 2008-08-29 2010-03-04 学校法人北里研究所 Method for detecting the drug effects of dna methylation-inhibitors
EP3442584B1 (en) 2016-03-15 2021-07-28 Seagen Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
EP3463463A4 (en) 2016-06-03 2020-01-15 Seattle Genetics, Inc. Combination of cd33 antibody drug conjugates with chemotherapeutic agents
US11191771B2 (en) 2016-06-09 2021-12-07 Seagen Inc. Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors
GEP20227357B (en) * 2017-06-22 2022-02-25 Servier Lab Combination of mcl-1 inhibitor and standard of care treatment for hematologic cancers, uses and associated pharmaceutical compositions
CN110869029A (en) * 2017-07-09 2020-03-06 拜欧赛特有限公司 Combination cancer therapy
CN113631193A (en) * 2019-01-28 2021-11-09 德州大学系统董事会 Metal chelator combination therapy for the treatment of cancer
CN110123825B (en) * 2019-05-28 2021-11-30 宁波市鄞州人民医院 Pharmaceutical composition containing demethoxydaunorubicin
IL302252A (en) * 2020-10-27 2023-06-01 Vor Biopharma Inc Compositions and methods for treating hematopoietic malignancy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
CN1468259A (en) * 2000-08-08 2004-01-14 ͨ��ҽ�ƹ�˾ Immunotherapy for chronic myelocytic leukemia

Also Published As

Publication number Publication date
AU2010201113A1 (en) 2010-04-15
BR0215935A (en) 2005-08-09
AU2002348178A1 (en) 2004-06-03
JP2006508119A (en) 2006-03-09
CA2504611A1 (en) 2004-05-27
NO20052009D0 (en) 2005-04-25
EP1575582A4 (en) 2009-03-11
CN1720044A (en) 2006-01-11
NO20052009L (en) 2005-06-27
MXPA05004711A (en) 2005-08-03
EP1575582A1 (en) 2005-09-21
WO2004043461A1 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
CR7804A (en) COMBINED THERAPY FOR THE TREATMENT OF ACUTE LEUKEMIA AND MYELODISPLASIC SYNDROME
AR027355A1 (en) THIAZOLIDINCARBOXILIC ACIDS
ECSP105178A (en) ARIL UREA COMPOUNDS IN COMBINATION WITH OTHER CITTATIC OR CYTOTOXIC AGENTS FOR CANCER TREATMENT IN HUMANS
CL2008002139A1 (en) Dimer compounds derived from pyrrolo [2,1c] [1,4] benzodiazepine-5 -one (tomaimycin), a conjugate comprising them; procedure of preparation of conjugates; pharmaceutical composition comprising the compounds or conjugates; and use of compounds and conjugates in the treatment of cancer.
UY29868A1 (en) NUCLEOCIDOS 4 MODIFIED AS ANTIVIRAL AGENTS
CR8146A (en) METHODS TO TREAT CANCERES USING 3- (4-AMINO -1-OXO-1,3 DIHIDRO-ISOINDOL-2-IL) POLYPORMAL FORMS - PIPERIDINA-2,6-DIONE
CL2007002994A1 (en) HETEROCICLIC DERIVATIVE COMPOUNDS CONTAINING SULFAMOIL, INHIBITORS OF HSP90; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF CANCER, SUCH AS CANCER OF BREAST, COLON AND PROSTATE, BETWEEN OTHERS.
CL2008002224A1 (en) Pharmaceutical composition comprising a) a compound selected from paclitaxel, docetaxel, ispinesib, thiazoloquinoline, among others, and b) aurora kinase inhibitor compounds selected from imidazopyrazine derivatives; use of combination and composition to treat cancer.
CL2009001170A1 (en) Pharmaceutical composition for oral administration comprising immediate release 5-azacitidine without enteric coating; and its use for the treatment of a disease associated with abnormal cell proliferation, such as myelodysplastic syndrome, acute myelogenous leukemia and lung cancer, among others.
AR013269A1 (en) PRODUCT CONTAINING AT LEAST A DOUBLE FILAMENT RNA COMBINED WITH AT LEAST AN ANTI-VIRAL AGENT, FOR THERAPEUTIC USE IN THE TREATMENT OF A VIRAL DISEASE, ESPECIALLY OF VIRAL HEPATITIS
CR9846A (en) 2-AMINO-7,8-DIHIDRO-6H-PIRIDO [4,3-D] PIRIMIDINA-5-ONAS
WO2004087713A8 (en) Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
MX368013B (en) Cancer treatment.
CR6404A (en) USEFUL REPLACED BICYCLE DERIVATIVES AS AGENTS AGAINST CANCER
UY29796A1 (en) NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS
WO2008101214A3 (en) Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
MX2021015993A (en) Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome.
AR023616A1 (en) COMBINED PREPARATIONS UNDERSTANDING ANTHRACICLINE DERIVATIVES
AR112103A1 (en) COMPOUNDS FOR THE TREATMENT OF TNBC
WO2005076888A3 (en) Anti-cancer therapies
HRPK20041072B3 (en) Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
SV2009003403A (en) EXTRUDED WITH IMPROVED FLAVOR MASK
AR032989A1 (en) A PHARMACEUTICAL COMPOSITION USEFUL FOR THE TREATMENT OF CANCER
SV2008002856A (en) 2-AMINO-7, 8-DIHIDRO-6H-PIRIDO [4,3-D] PIRIMIDINA-5-ONAS
AR067420A1 (en) ANTITUMORAL COMBINATIONS CONTAINING AN INHIBITING AGENT OF THE ENDOTELIAL VASCULAR GROWTH FACTOR (VEGF) AND IRINOTECAN

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)